Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,260 across all filing types
Latest filing 2025-02-14 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed document as per the captioned subject for your reference.
Regulatory Filings
2025-02-14 English
Copy of Newspaper Publication
Regulatory Filings
2025-02-14 English
Please find the enclosed document as per the captioned subject for your reference.
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from AstraZeneca Pharma India Limited dated February 11, 2025, reporting the unaudited financial results for the quarter and nine months ended December 31, 2024. It includes comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, earnings per share, and notes explaining exceptional items and accounting standards applied. The document also contains an Independent Auditors' Review Report on the unaudited financial results, confirming the review of interim financial information under Indian Accounting Standard 34 (Ind AS 34) for interim financial reporting. Additionally, there is a press release summarizing the financial performance and management commentary. The presence of unaudited financial statements for a quarter and nine months period, along with the auditor's limited review report, clearly identifies this as an Interim / Quarterly Report. The document is lengthy (15,000 characters), contains substantive financial data and analysis, and is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-02-11 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is dated February 11, 2025, and is from AstraZeneca Pharma India Limited. It contains unaudited financial results for the quarter and nine months ended December 31, 2024, including detailed financial tables with income, expenses, profit, and earnings per share. It also includes notes explaining accounting standards, exceptional items, and audit committee review. There is an Independent Auditors' Review Report on the unaudited financial results, referencing Indian Accounting Standard 34 for interim financial reporting. Additionally, there is a press release summarizing the financial performance for the quarter ended December 31, 2024, highlighting revenue growth and business segment performance. The document is comprehensive, contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and nine months), and is not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-02-11 English
Please find the enclosed document as per the captioned subject for your reference.
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the third quarter and nine months ended December 31, 2024. It contains summarized financial performance data for Q3 2024 and year-to-date figures, along with commentary from company executives. The document is not a full quarterly report but an initial announcement of quarterly financial results. It is not a detailed interim report with full financial statements, nor is it an annual report or audit report. The presence of key appointments and recognitions is typical in earnings releases. Therefore, the document fits the definition of an Earnings Release (ER). The document length (6912 characters) supports it being a press release rather than a full report.
2025-02-11 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated February 11, 2025, announcing unaudited financial results for the quarter and nine months ended December 31, 2024. It contains summarized financial performance data for Q3 2024 and year-to-date, along with commentary from the CFO and Managing Director. The document is titled as a 'News Release' and includes highlights of revenue growth and key business milestones. It does not contain full detailed financial statements or comprehensive analysis typical of an Interim/Quarterly Report (IR), but rather a summarized earnings announcement. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2025-02-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.